Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise

Neurosense Therapeutics

31/03/2026 14:31

Overview

Israel biotechnology firm's 2025 net loss widened, with increased R&D and admin expenses

Company advanced PrimeC into late-stage clinical development with FDA-cleared Phase 3 ALS trial

Statistically significant survival benefit reported for PrimeC, including 65% reduction in risk of death

Outlook

Company expects additional biomarker readouts from PARADIGM and Phase 2 Alzheimers study in 2026

NeuroSense plans pre-NDS meeting with Health Canada in May 2026 and potential NDS submission

Company continues preparing for initiation of Phase 3 PARAGON trial in ALS

Result Drivers

INCREASED R&D SPENDING - Higher research and development expenses mainly due to increased share-based payment expenses and higher salaries, partly offset by lower subcontractor costs

ADMIN COSTS - General and administrative expenses rose due to higher share-based compensation

Company press release: ID:nPn4J9TsNa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$0.44
FY Operating Income
-$11.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $8.25, about 1,028.6% above its March 30 closing price of $0.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)